Patent: 7,731,959
Summary for Patent: 7,731,959
| Title: | Antagonists of neuropilin receptor function and use thereof |
| Abstract: | The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. |
| Inventor(s): | Michael Klagsbrun, Shay Soker, Hua-Quan Miao, Seiji Takashima |
| Assignee: | Boston Childrens Hospital |
| Application Number: | US10/104,440 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,731,959
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2022-03-22 |
| Eusa Pharma (uk) Limited | SYLVANT | siltuximab | For Injection | 125496 | April 23, 2014 | ⤷ Start Trial | 2022-03-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
